Status:
ACTIVE_NOT_RECRUITING
PRediction Of Glycemic RESponse Study
Lead Sponsor:
Scripps Translational Science Institute
Collaborating Sponsors:
CareEvolution Healthcare Technology
Tempus AI
Conditions:
Glycemic Response
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of PROGRESS is to engage and intensively monitor 1000 individuals' dietary intake, activity levels, and continuous glucose values over 10 days, link to clinical events out to 3-years, and ...
Detailed Description
Interested individuals will be directed to download the MyDataHelps™ (CareEvolution) mobile app to register and provide informed consent as well as prompt completion of surveys, share their electronic...
Eligibility Criteria
Inclusion
- Age ≥ 18 years.
Exclusion
- Type 1 diabetes mellitus
- Unable to participate in or comply with any of the testing modules asked during the study
- Currently pregnant
- Prior bariatric surgery
- Chemotherapy or radiation treatment for cancer in the past year
- Inflammatory bowel disease
- Known skin allergy to adhesives and nickel (or other contraindications to continuous glucose monitoring)
- Currently taking any oral steroids(these medications may impact glucose levels)
- Antibiotic use in the last 3 months prior to the start of the study or planned use during the duration of the study
- Non-dietary, supplemental probiotic use either daily or weekly
- Hospice care
- End stage renal disease
Key Trial Info
Start Date :
June 8 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2025
Estimated Enrollment :
1070 Patients enrolled
Trial Details
Trial ID
NCT04881019
Start Date
June 8 2021
End Date
December 31 2025
Last Update
May 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Scripps Research Translational Institute
San Diego, California, United States, 92037